US OptionsDetailed Quotes
CBUS241220P22500
- 0.00
- 0.000.00%
15min DelayClose Dec 23 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover0.00%IV-692.25%PremiumDec 20, 2024Expiry Date19.66Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cibus Inc Stock Discussion
Cibus, Albaugh LLC and RTDC Company Limited Affirm Collaboration to Enable Commercialization of Cibus' First Gene Edited Weed Management Solution for U.S. Rice Growers
Monday, 16th December at 7:00 am
Cibus' Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.
Cibus and its partners Albaugh and RTDC Continue Their Research and Development Collaboration to Enable Commerciali...
Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola
Cibus (NASDAQ: CBUS) has successfully completed gene edits in Canola for its 4th mode of action targeting Sclerotinia (White Mold) resistance trait, with greenhouse results expected in Q1 2025. This achievement follows positive field trial results from their 2nd mode of action, which demonstrated enhanced disease resistance. Sclerotinia is identified as the most signif...
Cibus Confirms its Herbicide Tolerance (HT2) Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola
Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice
Cibus (Nasdaq: CBUS) has announced positive initial field trial results for a novel weed management solution in rice using stacked gene edited herbicide tolerant traits. The trials showed that using two herbicides provided excellent weed control. This approach could enable farmers to use a comprehensive weed management system with two different modes of action, p...
$Grove Collaborative (GROV.US)$ 16m float / 74% institutional/ 30% CTB
$Acorda Therapeutics (ACOR.US)$ 1.2m float/ 18% institutional/ 37% CTB
$Verastem (VSTM.US)$ 16m float / 40% institutional/ 18% CTB
$Cibus Inc (CBUS.US)$ 16m float / 12% institutional
$Bone Biologics (BBLG.US)$ 27m float / 17% institutional/ 127% CTB
$Greenlane (GNLN.US)$ 1.5m float/ 17% institutional/ 35% CTB
$VistaGen Therapeutics (VTGN.US)$ 7.2m floa...
No comment yet